Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024!
This year’s groundbreaking approvals include:
- Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema).
- mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV.
- Livdelzi (seladelpar) by Gilead, a second-line treatment for primary biliary cholangitis (PBC).
- Capavaxive by Merck, a pneumococcal vaccine for preventing invasive pneumococcal disease in adults.
- Ohtuvayre (ensifentrine) by Verona, the first inhaled treatment for the maintenance of COPD, allowing for broad use in COPD patients.
Thank you to our dedicated teams, partners, and patients for making this impact possible. This is why we do what we do, and the journey continues!
